Royce & Associates LP X4 Pharmaceuticals, Inc Transaction History

Royce & Associates LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.72 - $1.46 $33,120 - $67,160	-46,000 Reduced 11.84%	342,363 $475,000
Q4 2023 Feb 12, 2024	BUY	$0.61 - $0.99 $164,307 - $266,663	269,357 Added 226.34%	388,363 $326,000
Q3 2023 Nov 09, 2023	BUY	$1.03 - $2.02 $67,481 - $132,342	65,516 Added 122.48%	119,006 $129,000
Q2 2023 Aug 07, 2023	BUY	$0.82 - $2.49 $43,861 - $133,190	53,490 New	53,490 $103,000

101

101M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $36.4M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.